The IMI PROTECT project: Purpose, organizational structure, and procedures

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue , 2016, Pages 5-10

  Reynolds, Robert F ^a   Kurz, Xavier ^b   de Groot, Mark C H ^c,d,w   Schlienger, Raymond G ^e   Grimaldi Bensouda, Lamiae ^f,r   Tcherny Lessenot, Stephanie ^g,x   Klungel, Olaf H ^c,d,w   Alvarez, Y ^b   Candore, G ^b   Durand, J ^b   Slattery, J ^b   Hasford, J ^h   Rottenkolber, M ^h   Schmiedl, S ⁱ   de Abajo Iglesias, F ^j   Gil, M ^j   Gonzalez, R ^j   Huerta Alvarez, C ^j   Martin, E ^j   Oliva, B ^j   Requena, G ^j   Amelio, J ^k   Brauer, R ^k   Downey, G ^k   Feudjo Tepie, M ^k   Schoonen, M ^k   Johansson, S ^l   Robinson, J ^m   Schuerch, M ^m   Tatt, I ^m   Garcia, L A ⁿ   Ruigomez, A ⁿ   Campbell, J ^o   Gallagher, A ^o   Ng, E ^o   van Staa, T P ^o   Demol, O ^p   Boudiaf, N ^q   Davis, K ^q   Logie, J ^q   Pimenta, J ^q   Beau Lejdstrom, R ^r   Abenhaim, L ^r   Rossignol, M ^r   Hesse, U ^s   Ronn P F ^s   Miret, M ^t   Fortuny, J ^u   Primatesta, P ^u   Rivero, E ^u   Schlienger, R ^u   Bate, A ^a   Gatto, N ^a   Ballarin, E ^v   Ferrer, P ^v   Ibanez L ^v   Laporte, J R ^v   Sabate M ^v   Abbing Karahagopian, V ^w   Ali, S ^w   de Bakker, D ^w   Belitser, S ^w   de Boer, A ^w   De Bruin, M L ^w   Egberts, A C G ^w   van Dijk, L ^w   Gardarsdottir, H ^w   Groenwold, R H ^w   Hoes, A W ^w   Leufkens, H G M ^w   Pestman, W ^w   Roes, K C B ^w   Souverein, P ^w   Rutten, F ^w   Uddin, J ^w   van den Ham, H A ^w   Voogd, E ^w   de Vries, F ^w   Udo, R ^w   Auclert, L ^x   Juhaeri, J ^x   Mazuranok, L ^x   Wise, L ^y   Irvine, D ^y   Dolin, P ^y   Gasse, C ^z   more..

^a PFIZER INC   (United States)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e NOVARTIS PHARMA AG   (Switzerland)

^f University Versailles Saint Quentin UVSQ   (France)

^g SANOFI   (France)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ Witten University   (Germany)

^j Agencia Espanola de Medicamentos y Productos Sanitarios   (Spain)

^k AMGEN INC   (United States)

^l ASTRAZENECA   (United Kingdom)

^m Roche   (Spain)

ⁿ Roche ^*  (Spain)

^o Clinical Practice Research Datalink   (United Kingdom)

^p Department of Clinical Research   (United States)

^q GLAXOSMITHKLINE   (United States)

^r GlaxoSmithKline Research and Development LTD ^*  (United States)

^s Sundhedsstyrelsen   (Denmark)

^t MERCK KGAA   (Germany)

^u NOVARTIS   (Switzerland)

^v Fundacion Institut Catala de Farmacologia   (Spain)

^w UTRECHT UNIVERSITY   (Netherlands)

^x Sanofi   (India)

^y Takeda Ltd   (India)

^z AARHUS UNIVERSITY   (Denmark)

more..

Author keywords

Electronic healthcare databases; European Medicines Agency; Innovative Medicines Initiative; Methodology; Observational studies; Pharmacoepidemiology; PROTECT

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ACUTE HEART INFARCTION; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; EUROPEAN MEDICINES AGENCY; HEART INFARCTION; HIP FRACTURE; HUMAN; LIVER INJURY; METHODOLOGY; NEOPLASM; OBSERVATIONAL STUDY; ORGANIZATIONAL STRUCTURE; OUTCOMES RESEARCH; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REGISTER; RISK BENEFIT ANALYSIS; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; ADVERSE DRUG REACTION; EUROPEAN UNION; STANDARDS;

DRUG INDUSTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPEAN UNION; HUMANS; PHARMACOEPIDEMIOLOGY;

EID: 84962878589     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3933     Document Type: Article

References (65)

1. Strom BL. Pharmacoepidemiology: response to a challenge. Pharmacoepidemiol Drug Saf 1995; 4: 11-14.
2. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology (5th edn). Wiley-Blackwell: Oxford, 2012.
3. Hamburg MA. The growing role of epidemiology in drug safety regulation. Epidemiology 2011; 22(5): 622-624. doi:10.1097/EDE.0b013e31822837ba.
4. Lewis MA. The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 1998; 179: 1086-1097.
5. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153(9): 600-606. doi:10.7326/0003-4819-153-9-201011020-00010.
6. Studying the science of observational research: empirical findings from the Observational Medical Outcomes Partnership. Drug Saf 2013; 36(Supplement 1): S1-S204.
7. Observational Medical Outcomes Partnership (OMOP). Available at http://www.omop.org [29 September 2015].
8. The US Food and Drug Administration. FDA's Sentinel Initiative. Available at http://www.fda.gov/Safety/FDAsSentinelInitiative [29 September 2015].
9. Trifirò G, Pariente A, Coloma PM, et al. Fourrier-Reglat A; EU-ADR group. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 2009; 18(12): 1176-1184. doi:10.1002/pds.1836.
10. Madigan D, Ryan P. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research. Epidemiology 2011; 22(5): 629-631. doi:10.1097/EDE.0b013e318228ca1d.
11. Hernán MA. Epidemiologic studies, warts and all, are our best chance. Epidemiology 2011; 22(5): 636-637. doi:10.1097/EDE.0b013e318228cccb.
12. Taubes G. Epidemiology faces its limits. Science 1995; 269: 164-169.
13. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004; 57(12): 1223-1231.
14. CPRD. The UK Clinical Practice Research Datalink. Available at http://www.cprd.com/intro.asp [29 September 2015].
15. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-3210.
16. Van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285: 1850-1855.
17. De Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006; 35: 1301-1308.
18. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166: 1563-1566.
19. Van Staa TP, Leufkens B, Cooper C. Bone loss and inhaled glucocorticoids. N Engl J Med 2002; 346: 533-535.
20. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004; 292: 1326-1332.
21. De Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 2007; 80: 69-75.
22. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657-663. doi:10.1001/jama.2010.1098.
23. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444.
24. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953.
25. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-959. doi:10.1592/phco.28.8.951.
26. De Vries F, van Staa TP, Leufkens HG. Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers. Osteoporos Int 2010; 22: 1641-1642. doi:10.1007/s00198-010-1323-1.
27. De Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20: 1989-1998. doi:10.1007/s00198-009-0891-4.
28. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT). Available at http://www.imi-protect.eu [29 September 2015].
29. The Innovative Medicines Initiative (IMI). Available at http://www.imi.europa.eu [29 September 2015].
30. Ali MS, Groenwold RH, Belitser SV, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. J Clin Epidemiol 2015; 68(2): 112-121. doi:10.1016/j.jclinepi.2014.08.011.
31. Ali MS, Groenwold RH, Klungel OH. Propensity Scores methods and unobserved confounding imbalance: Comments on 'Squeezing the Balloon: Propensity Scores and Unmeasured Covariate Balance' by JM Brooks and RL Ohsfeldt. Health Serv Res 2014; 49(3): 1074-1082. doi:10.1111/1475-6773.12152.
32. Ali M, Groenwold RH, Pestman WR, Belitser SV, Hoes AW, de Boer A, Klungel OH. Time-dependent propensity score and collider-stratification bias: an example of beta2-agonist use and the risk of coronary heart disease. Eur J Epidemiol 2013; 28(4): 291-299. doi:10.1007/s10654-013-9766-2.
33. Ali MS, Groenwold RH, Pestman WR, et al. Propensity score balance measures in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf 2014; 23(8): 802-811. doi:10.1002/pds.3574.
34. Ali MS, Uddin MJ, Groenwold RH, et al. Quantitative falsification of instrumental variables assumption using balance measures. Epidemiology 2014; 25(5): 770-772. doi:10.1097/EDE.0000000000000152.
35. Belitser SV, Martens EP, Pestman WR, Groenwold RH, de Boer A, Klungel OH. Measuring balance and model selection in propensity score methods. Pharmacoepidemiol Drug Saf 2011; 20: 1115-1129. doi:10.1002/pds.2188.
36. Groenwold RH, Klungel OH, Altman DG, van der Graaf Y. Hoes AW and Moons K. Adjustment for continuous confounders: how to prevent residual confounding. CMAJ 2013; 185(5): 401-406. doi:10.1503/cmaj.120592.
37. Groenwold R, Klungel O, Grobbee D, Hoes A. Selection of confounding variables should not be based on observed associations with exposure. Eur J Epidemiol 2011; 26(8): 589-593. doi:10.1007/s10654-011-9606-1.
38. Groenwold RH, de Vries F, de Boer A, Pestman WR, Rutten FH, Hoes AW, Klungel OH. Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction. Pharmacoepidemiol Drug Saf 2011; 20: 1130-1137. doi:10.1002/pds.2251.
39. Groenwold RH, Uddin MJ, Roes KCB, et al. Instrumental variable analysis in randomized trials with non- compliance and observational pharmacoepidemiologic studies. OA Epidemiology 2014; 2(1): 9.
40. Hazelbag CM, Klungel OH, van Staa TP, de Boer A, Groenwold RH. Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. Ann Epidemiol 2015; 25(8): 590-596. doi:10.1016/j.annepidem.2015.03.019.
41. Klungel OH, Jamal Uddin M, de Boer A, Belitser SV, Groenwold RH, Roes KC. Instrumental Variable Analysis in Epidemiologic Studies: An Overview of the Estimation Methods. Pharm Anal Acta 2015; 6: 353. doi:10.4172/2153-2435.1000353.
42. Ng ES, Klungel OH, Groenwold RH, van Staa TP. Risk patterns in drug safety study using relative times by accelerated failure time models when proportional hazards assumption is questionable: an illustrative case study of cancer risk of patients on glucose-lowering therapies. Pharm Stat 2015; 14(5): 382-394. doi:10.1002/pst.1697.
43. Uddin MJ, Groenwold RH, de Boer A, et al. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study. Pharmacoepidemiol Drug Saf 2014; 23(2): 165-177. doi:10.1002/pds.3555.
44. Uddin MJ, Groenwold RH, van Staa TP, et al. Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf 2015; 24(5): 468-477. doi:10.1002/pds.3724.
45. Ferrer P, Ballarín E, Sabaté M, et al. Sources of European drug consumption data at a country level. Int J Public Health 2014; 59(5): 877-887. doi:10.1007/s00038-014-0564-8.
46. Ferrer P, Ballarín E, Sabaté M, et al. Antiepileptic drugs and suicide: a systematic review of adverse effects. Neuroepidemiology 2014; 42: 107-120. doi:10.1159/000356807.
47. Ferrer P, Rafaniello C, Sabaté M, et al. Cross-national comparison of antiepileptic drug consumption: Catalonia, Denmark and Norway, 2007-2011. Epidemiol Biostat Public Health 2014; 11(3:e9405 1-9). doi:10.2427/9405.
48. Khong TP, de Vries F, Goldenberg JSB, et al. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int 2012; 91(1): 24-31. doi:10.1007/s00223-012-9603-8.
49. Prieto-Alhambra D, Petri H, Goldenberg JSB, et al. Excess risk of hip fractures attributable to the use of antidepressants in 5 European countries and the United States. Osteoporos Int 2014; 25(3): 847-855. doi:10.1007/s00198-013-2612-2.
50. Rottenkolber M, Fischer R, Ibáñez L, et al. Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial. BMC Pulm Med 2015; 15: 55. doi:10.1186/s12890-015-0051-x.
51. Rottenkolber M, Rottenkolber D, Fischer R, et al. Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients: a systematic review. Respir Med 2014; 108(8): 1075-1090. doi:10.1016/j.rmed.2014.05.014.
52. Sabaté M, Ferrer P, Ballarín E, et al. Inpatient drug consumption in Europe: national data sources and review of publications on a selected group of medicines (PROTECT project). Basic Clin Pharmacol Toxicol 2015; 116(3): 201-211. doi:10.1111/bcpt.12358.
53. Sabaté M, Pacheco JF, Ballarín E, et al. A compilation of research working groups on drug utilization across Europe. BMC Res Notes 2014; 7: 143. doi:10.1186/1756-0500-7-143.
54. Schmiedl S, Fischer R, Ibáñez L, et al. Utilisation and off-label prescriptions of respiratory drugs in children. PLoS One 2014; 9(9). doi:10.1371/journal.pone.0105110.
55. Erikson E, Ibáñez L. Secondary data sources in drug utilization research. In Drug Utilization Research. Elseviers M, Wettermark B, Anderson M, et al. (eds). John Wiley & Sons Inc., 2016.
56. Vlahovic-Palcevski V, Wettermark B, Ibáñez L and VanderStichele R. Comparison of drug utilization across different geographical areas. In Drug Utilization Research. Elseviers M, Wettermark B, Anderson M, et al. (eds.). John Wiley & Sons Inc., 2016.
57. Abbing-Karahagopian V, Huerta C, Souverein PC, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol 2014; 70(7): 849-857. doi:10.1007/s00228-014-1676-z.
58. De Groot MC, Schuerch M, de Vries F, et al. Antiepileptic drug use in seven electronic health record databases in Europe: a methodological comparison. Epilepsia 2014; 55(5): 666-673. doi:10.1111/epi.12557.
59. Requena G, Abbing-Karahagopian V, Huerta C, et al. Incidence rates and trends of hip/femur fractures in five European countries: comparison using e-healthcare records databases. Calcif Tissue Int 2014; 94(6): 580-589. doi:10.1007/s00223-014-9850-y.
60. Rottenkolber M, Voogd E, van Dijk L, et al. Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database study. PLoS One 2015; 10(2). doi:10.1371/journal.pone.0117628.
61. Rottenkolber M, Voogd E, van Dijke L, et al. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs. Respir Med 2015; 109(7): 828-837. doi:10.1016/j.rmed.2015.01.010.
62. Ruigómez A, Brauer R, Rodríguez LA, et al. Ascertainment of acute liver injury in two European primary care databases. Eur J Clin Pharmacol 2014; 70(10): 1227-1235. doi:10.1007/s00228-014-1721-y.
63. Abbing-Karahagopian V, Kurz X, de Vries F, et al. Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the PROTECT Project. Curr Clin Pharmacol 2014; 9(2): 130-138. doi:10.2174/1574884708666131111211802.
64. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Available at http://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml [29 September 2015].
65. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Available at http://www.encepp.eu/encepp/studiesDatabase.jsp [29 September 2015].